PATENT CLAIM ANALYSIS

Application Number: 15760170
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "450000"]

Abstract:
Lipid nanoparticles and methods of making and using the same, including pharmaceutical compositions and kits, and the targeted delivery of drugs in various treatment methods. The nanoparticle formulation includes phospholipids, triglycerides, cholesterol, cholesteryl ester, apolipoprotein E3 (ApoE3), and a lipophilic therapeutic agent.

Claim (Index 24):
A pharmaceutical composition that has been reconstituted from the lyophilized composition according to  claim 22 , therein the therapeutic agent is Docetaxel and the composition does not contain Polysorbate 80, and wherein a molar ratio of Docetaxel molecules per each recombinant ApoE3 molecule in the reconstituted composition is from 45-140.

Metadata:
- Claim Count in Document: 66.0
- Percentile: 90.0
- Lexical Diversity: 1.35897
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10724833', '11648808', '11802197', '11513756', '11802727']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7419586279469109
- 35 USC 102 Novelty (BERT): 0.5203613217377389
- Combined Prediction Score: 0.7197988973259938
- Mean Citation Score: 279.559728
- Max Citation Score: 291.0936
- Similarity Product: 200.7783450744152

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test